AFINITOR is contraindicated in patients with hypersensitivity to everolimus, other rapamycin derivatives, or any excipients.
Noninfectious pneumonitis was reported in up to 19% of patients...
Encourage your patients to find out if they are eligible to enroll in the Universal Co-pay Program by visiting www.CoPay.NovartisOncology.com or calling 1-877-577-7756.
Give your patients an informational brochure to help them learn more about advanced kidney cancer and if AFINITOR may be the right choice for them.
*66% (86/130) of metastatic clear cell RCCs obtained from Canadian and US patients.
†Based on analysis of primary tumor tissues and metastatic lesions (not overall response).
Abbreviations: mTOR, mammalian target of rapamycin; RCC, renal cell carcinoma.
Important Safety Information
AFINITOR is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.
Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors:
Impaired Wound Healing:
Laboratory Tests and Monitoring:
Please see full Prescribing Information.